Paper Details

  1. Home
  2. Paper Details

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.

Author: HameedMeera R, KapurSakshi, LevinMiles B, XiaoHan, ZakowskiMaureen F

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Cabozantinib, a tyrosine kinase inhibitor, is approved for treating metastatic medullary thyroid carcinoma. Although it can cause side effects such as stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension, and diarrhea, most patients tolerate the recommended dose of 140 mg daily. This study reports two cases of patients with progressive metastatic medullary thyroid carcinoma who responded well to therapy with cabozantinib.
Paper Details　
Original Abstract of the Article :
Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, mos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649879/

データ提供：米国国立医学図書館（NLM）

Cabozantinib: A Beacon of Hope for Metastatic Medullary Thyroid Carcinoma

Medullary thyroid carcinoma (MTC), a type of thyroid cancer, can spread to other parts of the body, presenting a significant challenge for treatment. This research explores the potential of cabozantinib, a tyrosine kinase inhibitor, in managing metastatic MTC. The study focuses on two patients with advanced MTC who underwent treatment with cabozantinib, reporting their responses to this targeted therapy.

Imagine a shimmering oasis in the arid landscape of MTC, where a new treatment emerges, offering hope for individuals facing this challenging disease. This research, like a beacon of light, explores the potential of cabozantinib to provide a glimmer of relief for patients with metastatic MTC.

Cabozantinib: A Promising Treatment Option

The two case reports presented in this study demonstrate the potential of cabozantinib in effectively treating metastatic MTC. The patients experienced positive responses to therapy, showcasing the drug's ability to manage disease progression and improve quality of life.

Navigating the Treatment Landscape of MTC

This research underscores the evolving landscape of cancer treatment, with new drugs like cabozantinib offering hope for patients with previously limited treatment options. It highlights the importance of exploring personalized therapies to combat the challenges posed by metastatic cancers.

Dr.Camel's Conclusion

This research is like discovering a hidden wellspring in the vast desert of MTC, offering a potential lifeline for patients facing metastatic disease. Cabozantinib, like a refreshing oasis, provides hope and a new avenue for managing this challenging form of cancer.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-09-29
Further Info :

Pubmed ID

29147383

DOI: Digital Object Identifier

PMC5649879

Related Literature

Article Analysis
・Side Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.